16 results about "Myocardial function" patented technology

The application provides an antisense oligonucleotide Jag-i9 ASO and application thereof, relates to the technical field of biological medicine, and the antisense oligonucleotide Jag-i9 ASO has the sequence of 5'-ACTGGGCCCTGCACCTGA-3'. By providing the antisense oligonucleotide of a specific sequence, the binding site of target heterogeneous ribonucleoprotein K and the Jag2 gene is targeted, the expression of the pro-inflammatory Jag2 subtype is inhibited, the Jag2 gene splicing site can be accurately targeted, the heterogeneous ribonucleoprotein K binding function is specifically blocked, a targeted intervention means is provided for the treatment of myocardial ischemia-reperfusion injury, the generation of the pro-inflammatory subtype is inhibited by efficiently and accurately regulating the alternative splicing of a specific gene, myocardial cell apoptosis and inflammatory response are reduced, myocardial function is improved, and a new approach is provided for the prevention and treatment of myocardial ischemia-reperfusion injury, the treatment effect is improved, and the advantages of reducing side effects are achieved.

The invention provides a coronary heart disease echocardiogram pathological feature extraction method and system. Static structure features and myocardial function features of the heart of a target coronary heart disease patient are determined through an ultrasonic video stream of the heart of the target coronary heart disease patient; determining a region mapping matrix of a relationship between a coronary artery blood supply region of the target coronary heart disease patient and a myocardial injury state according to the static structural characteristics and the myocardial functional characteristics, and determining boundary sharpening development of a pathological region in the heart of the target coronary heart disease patient according to the region mapping matrix; acquiring a myocardial movement track of the target coronary heart disease patient, and determining a longitudinal strain gradient of a basal segment and a cardiac apex segment of the heart of the target coronary heart disease patient according to the myocardial movement track; and based on the boundary sharpening development and the longitudinal strain gradient of the pathological area and in combination with the clinical pathological data of the target coronary heart disease patient, generating the cardiac physical characteristics of the target coronary heart disease patient. According to the scheme, the static structure and the dynamic function of the heart can be effectively associated and fused to extract the coronary heart disease echocardiogram features.

The invention relates to the technical field of food biology, in particular to a high-activity fermented astragalus mongholicus and red date compound for improving myocardial function, which is prepared by taking Xinjiang Qiang red dates and astragalus mongholicus as main raw materials and matching cellulase, pectinase, beta-glucanase and hydroxypropyl-beta-cyclodextrin. In the preparation process, gradient freezing-microwave pretreatment and ternary composite enzymolysis synergistic wall breaking are adopted, quaternary strains of bifidobacterium longum, bacillus subtilis, saccharomyces cerevisiae and lactobacillus plantarum are compounded, adenosine concentration response type staged solid-state fermentation is performed, and microcapsule embedding stabilizing treatment is performed to obtain the product. The content of cAMP in the product is greater than or equal to 13.0 mu g / g, and the content of calycosin-7-glucoside in astragalus membranaceus is greater than or equal to 1.9 mg / g. The compound can be used for preparing myocardial ischemia pretreatment health-care food and a pharmaceutical composition for adjuvant therapy in the myocardial infarction recovery period, and the dosage forms comprise chewable tablets, oral liquid, capsules and the like.

The present invention relates to a composition for preventing or treating diabetic cardiomyopathy comprising an MsrB2 activator as an active ingredient. The MsrB2 activator disclosed in the present invention suppresses oxidative damage of ROS, induces autophagy in mitophagy, increases mitochondrial regeneration and biosynthesis in diabetic heart tissue, thereby suppressing overall myocardial function decline, so that it can be effectively used in a pharmaceutical composition or health food composition for preventing or treating diabetic cardiomyopathy, particularly diabetic heart disease in lean diabetes.

Provided are: cardiomyocytes with which, by overexpressing NCAM1 in iPS cell-derived cardiomyocytes, iPS cell-derived cardiomyocytes having high adhesion ability can be obtained, and by producing EHT using the same, the organization of the EHT can be further promoted and the function of the EHT can be enhanced; a cellular tissue-like structure; and a method for improving the function of cardiomyocytes. Provided are cardiomyocytes into which an expression vector of an NCAM1 protein has been introduced. Moreover, provided are: a cellular tissue-like structure comprising said cardiomyocytes; and a method for improving the function of cardiomyocytes, the method comprising a step for inducing the expression of an NCAM1 protein in cardiomyocytes.

The invention discloses an application of Fc-Elabeta-32 in preparation of a medicine for treating sepsis, and also comprises a preparation method of the Fc-Elabeta-32, and the preparation method comprises the step of fusing an Fc structural domain of human immune globulin IgG with Ela-32 to generate the Fc-Ela-32. The application has the advantages that by preparing and using the Fc-Elabel-32, the survival rate of sepsis mice is remarkably increased in an experiment, the cardiac function is remarkably improved, meanwhile, the myocardial injury index is remarkably reduced, myocardial dysfunction caused by sepsis is relieved, and the Fc-Elabel-32 can be used as a potential treatment medicine for sepsis.

The application discloses a compound preparation beneficial to muscle nutrition, which is composed of yeast extract powder, yeast beta-1, 3-glucan and ginsenoside at a weight ratio of 8:1:1, and contains 200-800 mg of yeast extract powder in each unit of the preparation; wherein the essential amino acids beneficial to muscle nutrition include three branched-chain amino acids, specifically isoleucine, leucine and valine, and the ratio coefficient of the branched-chain amino acids is 1-1.2, and the ratio coefficient range is 0.94-1.14. The compound preparation can improve the symptoms caused by muscle attenuation syndrome, such as muscle weakness, osteoporosis and myocardial function degradation, has the advantages of easy absorption, high safety, synergistic effect and the like, and is suitable for the old, the weak and the people with decreased sports ability.

The invention relates to an application of D-ribose in a cumulative exercise fatigue subject, which is beneficial to improving and / or protecting the myocardial function of the subject, improving the myocardial hypoxia tolerance of the subject, improving and / or protecting the skeletal muscle function of the subject, reducing the inflammation occurrence risk of the subject, and improving the exercise performance ability and exercise tolerance of the subject. And / or accelerating exercise fatigue recovery.

This invention discloses a method and system for predicting the prognosis of myocardial function in sepsis based on imidazole propionate targeted intervention. The method includes: firstly, collecting baseline characteristic data of sepsis patients and dynamic response data after imidazole propionate targeted intervention, and simultaneously recording time parameters from sepsis diagnosis to intervention initiation. Then, transforming the data according to preset standardization rules to obtain metabolic characteristics, myocardial function comprehensive data, mitochondrial function comprehensive data, and intervention response parameters, filtering out abnormal data and retaining valid data. Subsequently, the standardized data are substituted into a multi-parameter nonlinear weighted model fusing exponential and logistic regression functions to simultaneously calculate myocardial function recovery assessment values ​​and adverse prognostic risk values. Finally, based on the assessment results, prognostic grade intervals are defined, and differentiated intervention plans are formulated to complete the closed-loop treatment optimization of "prediction-intervention-dynamic reassessment." This improves the targeting and effectiveness of clinical diagnosis and treatment.

The invention relates to the technical field of myocardial function evaluation, and discloses a myocardial function evaluation method and device, a storage medium and computer equipment, and the method comprises the steps: applying acupuncture stimulation to a target object, and collecting a multi-channel magnetocardiogram signal and various physiological data of the target object; fusing the various physiological data and the multichannel magnetocardiogram signal to generate a physiological signal set, so as to dynamically adjust the load parameter of acupuncture stimulation; performing time alignment and space fusion on the multi-channel magnetocardiogram signal by using a multi-channel deep fusion network to obtain a multi-dimensional magnetocardiogram signal, and extracting feature information by using a deep learning feature extraction network; after the feature information and the multiple physiological data are fused, a cardiac load evaluation model is used for evaluating the myocardial function state of the target object, and the cardiac load capacity and / or the cardiac blood pumping efficiency are / is obtained. According to the method, the acupuncture load and the magnetocardiogram technology are combined, the myocardial function is dynamically, continuously and accurately evaluated, and a reliable basis is provided for clinical decision making.

This invention relates to a myocardial repair patch based on multi-material printing, its preparation, and its application, belonging to the field of bio-3D printing and regenerative medicine technology. The invention uses PLCL and GelMA hydrogel loaded with active cardiomyocytes as bio-inks, and introduces gelatin gel as a heat buffer material. An orthogonal network structure is constructed using multi-material bio-3D printing technology to prepare a myocardial repair patch with excellent dynamic adaptability to the myocardial interface and good biocompatibility. The myocardial injury repair patch prepared by this invention achieves a structure-function integrated design through the synergistic effect of the three materials, significantly overcoming the limitations of single materials in terms of mechanical properties, biological function, or thermal compatibility. The mechanical properties of the myocardial injury repair patch prepared by this invention can precisely match those of natural myocardium, while possessing high cell activity, effectively inhibiting fibrosis, improving myocardial function, and achieving true active repair. Furthermore, the process conditions are controllable, demonstrating good translational potential.

This invention discloses the application of NT5C1A as a therapeutic target for myocardial ischemia-reperfusion injury, belonging to the field of biomedical technology. Through proteomics screening and in vitro and in vivo experiments, this invention is the first to discover and demonstrate that NT5C1A is upregulated in the pathological process of MIRI, and is a key upstream factor regulating the AMPK / SIRT1 / PGC-1α signaling pathway. Overexpression of NT5C1A can effectively activate this pathway, synergistically regulating multiple downstream pathological processes: promoting the expression of mitochondrial fusion proteins Mfn-2 and OPA1, inhibiting the expression of the splitting protein DRP1; significantly promoting ATP production and improving energy metabolism disorders; and regulating the balance of apoptosis-related protein Bax / Bcl-2 expression, inhibiting cardiomyocyte apoptosis, ultimately reducing myocardial damage, improving myocardial function, and reducing the infarct area. This invention provides a new target and strategy for the precise intervention of MIRI.

The invention discloses a multi-mode epicardial fat and coronary artery calcification SPECT-CT image classification method and system. The method comprises the following steps: acquiring non-enhanced heart CT three-dimensional voxel data of a one-stop SPECT-CT; dividing the preprocessed CT three-dimensional voxel data by adopting threshold segmentation and connected domain analysis to obtain a coronary artery calcification region and an epicardial fat region; according to the coronary artery calcification region and the epicardial fat region, respectively calculating an Agatston calcification integral CACS, an epicardial fat volume and an epicardial fat density MEAN; according to the Agatston calcification integral CACS, the epicardial fat volume and the epicardial fat density MEAN, algorithm construction is conducted on the non-enhanced same-machine heart CT image through a pre-trained disordered multi-classification logistic regression model, image classification is conducted on SPECT-CT MPI, and the classification probability of four coronary artery structure-myocardial function combination categories is obtained; the method is only based on the non-enhanced heart CT scanning image, and the efficiency of one-stop SPECT-CT MPI image classification is improved.

The present invention provides a pharmaceutical composition used in a method for treating patients with single ventricle heart disease (SVHD) who have undergone the Fontan procedure. [Solution] A pharmaceutical composition for use in a method of treating a patient with SVHD to improve exercise capacity determined by improvement in the patient's VO2max and VO2 at the anaerobic threshold, wherein the SVHD patient has undergone Fontan surgery, and the method comprises administering to the SVHD patient an effective daily dose of the udenafil or a pharmaceutically acceptable salt thereof to treat the SVHD patient to improve exercise capacity determined by improvement in the patient's VO2max and VO2 at the anaerobic threshold, wherein the udenafil or a pharmaceutically acceptable salt thereof is administered in a total daily dose of about 175 mg.

The invention discloses a sepsis myocardial function prognosis prediction method and system based on imidazole propionic acid targeted intervention, and the method comprises the steps: firstly collecting baseline characteristic data of a sepsis patient and dynamic response data after imidazole propionic acid targeted intervention, and synchronously recording time parameters from sepsis diagnosis to intervention starting; and converting the data according to a preset standardization rule to obtain metabolic characteristics, myocardial function integration, mitochondrial function integration and intervention response parameters, screening and removing abnormal data, and reserving effective data. And then substituting the standardized data into a multi-parameter nonlinear weighted model fusing an exponential function and a logistic regression function, and synchronously calculating a myocardial function recovery evaluation value and a poor prognosis risk value. And finally, a prognosis level interval is delimited according to an evaluation result, a differential intervention scheme is formulated, and closed-loop treatment optimization of'prediction-intervention-dynamic reevaluation 'is completed. And the pertinence and effectiveness of clinical diagnosis and treatment are improved.

The application relates to a chamber wall segment motion estimation method based on confidence weight analysis of optical flow tracking, belongs to the technical field of ultrasonic image processing, and aims to solve problems such as the need to rely on subjective judgment of doctors and quality of echocardiographic images for myocardial functional abnormalities. Through optical flow calculation based on confidence weight analysis, motion vector decomposition and ROI region dynamic tracking, the dynamic motion field of each segment is accurately calculated, and finally, the myocardial segment motion time curve is obtained. The optical flow calculation method based on confidence weight analysis corrects the motion amount from top to bottom through a Gaussian pyramid algorithm, combines image correction technology, adds an image "confidence weight matrix", greatly reduces the calculation proportion of the "shadow" place by using the confidence weight coefficient, and thus improves the accuracy of optical flow calculation. Through motion vector decomposition, ROI region dynamic tracking is realized, the motion characteristic information of the myocardial segment is more accurately reflected, and the calculation precision of the myocardial chamber wall motion is improved.